

EVIDENCE MAP OF INDIRECT COSTS IN PSORIASIS AND PSORIATIC ARTHRITIS SINCE 1960

Alison Martin¹
¹Crystallise Ltd, Essex, UK alison.martin@crystallise.com

Objectives

To create an evidence map of studies reporting the indirect costs associated with psoriasis and psoriatic arthritis, and the geographical settings in which these studies were conducted.

Methods

We searched the heoro.com database (www.heoro.com) for abstracts reporting indirect costs in psoriasis or psoriatic arthritis published between 1960 and 1st June 2017. We analysed the abstracts identified by the search to determine the range of geographical locations, disease types, interventions and study methodologies. We presented the findings as an evidence map.

Results

Map of geographical location by disease

	Psoriasis	Psoriatic arthritis
Brazil	0	1
Canada	1	3
Egypt	1	0
France	2	0
Germany	4	2
Hungary	0	1
International	6	2
Iran	1	0

	Psoriasis	Psoriatic arthritis
Italy	3	2
Netherlands	3	0
Norway	0	1
Spain	1	1
Sweden	2	1
UK	4	2
USA	11	3
Unclear	2	0

Map of intervention by publication date

	1960-1999	2000-2004	2005-2009	2010-2014	2015-2017
Any targeted therapy	0	0	1	1	1
Adalimumab	0	0	1	4	3
Briakinumab	0	0	0	1	0
Calcipotriol	0	1	1	1	0
Coal tar	0	0	0	0	1
Corticosteroids	0	0	1	2	1
Cyclosporine	0	1	0	0	1
Dithranol	0	0	0	0	1
Etanercept	0	0	1	3	4
Fumaric acid	0	0	0	0	1
Golimumab	0	0	0	1	0
Infliximab	0	0	0	0	3
Methotrexate	0	0	0	0	1
Phototherapy	0	1	0	4	1
Retinoids	0	0	0	0	1
Secukinumab	0	0	0	0	1
Tacalcitol	0	0	1	0	0
Tazarotene	0	0	0	0	1
Ustekinumab	0	0	0	1	4
Other/ none/ unclear	2	1	10	16	6

Map of intervention by disease

	Psoriasis	Psoriatic arthritis
Any targeted therapy	2	1
Adalimumab	7	1
Briakinumab	0	1
Calcipotriol	3	0
Coal tar	1	0
Corticosteroids	4	1
Cyclosporine	1	1
Dithranol	1	0
Etanercept	5	4
Fumaric acid	0	1
Golimumab	1	0
Infliximab	2	1
Methotrexate	0	1
Phototherapy	6	0
Retinoids	0	1
Secukinumab	1	0
Tacalcitol	1	0
Tazarotene	1	0
Ustekinumab	3	2
Other/ none/ unclear	24	13

Map of intervention by geographical location

	Brazil	Canada	Egypt	France	Germany	Hungary	International	Iran	Italy	Netherlands	Norway	Spain	Sweden	UK	USA	Unclear
Any targeted therapy	0	0	0	0	0	0	1	0	2	0	0	0	0	0	0	0
Adalimumab	0	0	0	0	1	0	1	0	2	0	0	0	1	0	3	0
Briakinumab	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Calcipotriol	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1
Coal tar	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Corticosteroids	0	1	0	1	0	0	0	1	0	0	0	0	0	0	0	1
Cyclosporine	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0
Dithranol	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Etanercept	0	1	0	0	1	0	1	0	1	0	0	0	1	0	3	0
Fumaric acid	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Golimumab	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Infliximab	0	0	0	0	1	0	1	0	1	0	0	0	0	0	0	0
Methotrexate	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Phototherapy	0	0	0	0	0	0	1	1	0	2	0	0	0	1	1	0
Retinoids	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Secukinumab	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Tacalcitol	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Tazarotene	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Ustekinumab	0	0	0	0	1	0	1	0	0	0	0	0	0	0	3	0
Other/ none/ unclear	1	1	1	1	5	1	6	1	1	2	1	2	1	5	5	1

Numbers refer to number of studies identified for each category. Where a study is set in two or three locations, these are all listed separately. Studies set in five or more jurisdictions, or systematic reviews are classified as International. Studies are mapped to all relevant subcategories.

Conclusions

As with many diseases, there is a relative lack of published data on indirect costs of psoriasis and psoriatic arthritis, and 53% of studies reporting indirect cost data were from four jurisdictions: the US, Germany, the UK and Italy.